Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: A combination which comprises an effective amount of Her2/Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed.

Abstract: A method and an apparatus for determining the distributed power supply capacity to be accessed by a feed line of a power distribution network, and a storage medium, the method comprising: determining feed line loss on the basis of load information of power distribution network feed line access nodes and circuit parameters; on the basis of the feed line loss, determining three-phase voltage change values of the feed line circuit; using a single phase having the greatest voltage change amongst the voltage change values, determining a maximum active power for distributed power supply access under voltage constraints; comparing the current of the feed line corresponding to the maximum active power with a circuit current limit, and determining the distributed power supply capacity to be accessed by the feed line; the apparatus comprises a feed line information collection unit, a voltage drop unit, a quantitative calculation unit, and a results analysis unit.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: A method for identifying a pattern of a load cycle includes: performing statistics on a daily load of a system based on smart meter data; generating a curve of the daily load of the system according to the statistics on the daily load of the system; acquiring a result of clustering curves of loads of typical days by applying shape-based time sequence clustering analysis using the curve of the daily load of the system; and identifying a pattern of a load cycle according to the result of clustering the curves of the loads of the typical days.

Abstract: A standard conformance testing system and method for a CIM/E model of a power system and a storage medium include: converting the standards “Power Grid Common Model Description Specification (GB/T 30149)” and “Power Grid Operating Model Data Exchange Specification (DL/T 1380)” into practically operable testing rules, and performing automatic generation and verification of a CIM/E standard model and defect model. The testing system and method can improve the comprehensiveness and standardization of a CIM/E model standard compliance test, improving testing efficiency, promoting the level of standardization according to the CIM/E model in a power system software development process, and real time data exchange and interoperation between respective application systems, effectively supporting the safe and stable operation of a power grid.

Abstract: A container with a self-closing lid. The container has an open mouth with an upper rim with two lock elongate lock lever cutouts at opposite ends thereof, and two lock levers pivoted in the lock lever receiving cutouts, each lock lever having an upper rim with catch, and a bottom wall spaced below the upper rim. A lid sized and shaped to cover the open mouth of the container has an outer rim with a lower surface with downwardly directed projections at opposite ends thereof, and an upper surface with grooves formed thereon. When the lid placed on the open mouth of the container and pushed down, the projections will push on the bottom wall of the lock levers and rotate them inwardly causing the catches to snap into the grooves on lid to lock the lock levers on the lid.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Abstract: A filament lamp set in a drink bottle is provided, including a light emitting unit, wherein the outer side of the light emitting unit is sleeved by a connecting mechanism which can be fixedly connected with the mouth of a bottle body; an opening is formed in at least one end of the connecting mechanism; the light emitting unit extends out from the opening. The bottle body adopts the common drink bottle, by which the connecting mechanism can be matched with the mouth of the bottle so as to fix the bottle body in the connecting mechanism. In addition, the light emitting unit is sleeved by the bottle body. Based on the decorative patterns, colors and the like on the bottle body, different effects can be achieved by the emitted light and faculae, thus achieving the purpose of decoration.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of diseases such as cancer. Also provided are compositions comprising the compounds.